anti-inflammatory therapies - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.99 [0.94, 1.06]< 13%8 studies (8/-)56.7 %some concernserious moderatecrucial-
deaths 0.99 [0.94, 1.06]< 11%10 studies (10/-)57.5 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.42 [0.06, 2.87]< 172%2 studies (2/-)81.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.27 [0.09, 0.83]< 10%3 studies (3/-)98.9 %some concernnot evaluable moderateimportant-
clinical improvement 10.27 [1.17, 90.18]> 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 10.27 [1.17, 90.18]> 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 3.68 [0.18, 75.54]> 10%1 study (1/-)79.8 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 6.72 [1.50, 30.07]> 10%1 study (1/-)99.4 %some concernnot evaluable moderateimportant-
death or ventilation 0.94 [0.78, 1.15]< 170%2 studies (2/-)71.9 %some concernnot evaluable moderateimportant-
hospital discharge 0.98 [0.94, 1.03]> 10%1 study (1/-)19.3 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.94 [0.76, 1.15]< 134%5 studies (5/-)73.1 %some concernserious moderateimportant-
radiologic improvement (14-day) 2.87 [1.56, 5.28]> 10%1 study (1/-)100.0 %some concernnot evaluable moderateimportant-
ICU admission 0.92 [0.54, 1.58]< 10%2 studies (2/-)61.6 %some concernnot evaluable moderatenon important-
recovery 3.46 [1.05, 11.35]> 10%1 study (1/-)97.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.19 [0.04, 0.84]< 10%3 studies (3/-)98.6 %some concernnot evaluable moderateimportant-
adverse events 1.07 [0.53, 2.16]< 118%4 studies (4/-)42.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.